Intellectual Property

  Patent data keeps growing, but the time available to review it rarely does. For patent searchers, analysts, and IP teams, the issue is no longer only whether they can find relevant patents. Modern search tools can surface large sets of potentially useful references quickly. The more difficult question is what happens next: how do you work through hundreds of relevant patents without missing the disclosure that could change the outcome of a novelty search, invalidity analysis, FTO review, or state-of-the-art study? Traditional review workflows often rely on opening documents one by one, scanning abstracts, checking claims, and moving into specifications when something looks promising. That approach works for small sets, but it becomes inefficient when a searcher is dealing with 300 relevant records and a short deadline. The better approach is to start with questions. A question-first workflow changes the review process from passive reading to active interrogation. Instead of a...

  92% of U.S. patent applications get rejected at least once. Only 11.4%  clear  the USPTO on the first attempt with no rejections or amendments. And  nearly half  of all rejections (47%) come down to obviousness — meaning the examiner found prior art combinations the applicant's team either  didn't  know about or  didn't  account for when drafting claims. That's  not bad luck.  It's  a preparation problem. Here's  the part that really hurts: every time you amend a claim to overcome prior art, you permanently surrender that  claim  territory under the  Festo  doctrine. The Supreme Court made this clear — any narrowing amendment to overcome a prior art rejection creates a legal presumption that  you've  given up everything between what you originally claimed and what you ended up with.  There's  no taking it back in litigation. Translation: your patent gets weaker with every office ac...

Everyone is talking about semaglutide and tirzepatide. The blockbuster revenues, the obesity boom , the  reshaping of pharma valuations. But while the commercial story dominates headlines, a quieter and  arguably more  consequential race is playing out in patent offices across the globe. The question  isn't  whether GLP-1 generics are coming.  It's  when, where, and through how many layers of IP  they'll  have to fight. Here's  what most market commentary misses: GLP-1 drugs  don't  sit behind a single patent wall. They carry layered protection including compound patents, formulation patents, delivery device patents, and method-of-use claims, each expiring independently, across different  jurisdictions , on different timelines. Clearing the diabetes IP  doesn't  automatically open the door to the obesity  indication .  That's  a separate and newer thicket, with filings that extend exclusivity well ...